ANIK
Anika Therapeutics, Inc.
ANIK's outlook is improving, though it still trails on the overall score.
LLY
Eli Lilly and Company
LLY has the edge over ANIK overall, supported by stronger fundamentals and lower modeled downside.
ANIK Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Stable | |
| Strong |
ANIK's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is under pressure.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
ANIK PE Valuation
ANIK has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
ANIK Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for ANIK, with profitability improving.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
ANIK Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.91 | — |
| Q3 2026 | -$0.13 | +$2.15 |
| Q2 2026 | -$0.27 | +$3.88 |
| Q1 2026 | -$0.79 | +$3.09 |
| Q4 2025 | -$0.76 | +$3.09 |
| Q3 2025 | -$2.28 | +$4.36 |
| Q2 2025 | -$4.15 | +$0.91 |
| Q1 2025 | -$3.88 | +$1.36 |
| Q4 2024 | -$3.85 | +$1.79 |
ANIK is still losing money, but far less than before: $0.13 per share over the past year, against $6.64 at its worst in late 2024.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over ANIK on earnings quality, reporting a profit while its opponent remains loss making.
ANIK Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $30.6M | +10% |
| Q2 2026 | $32.6M | +16% |
| Q1 2026 | $29.6M | +13% |
| Q3 2025 | $27.8M | -28% |
| Q2 2025 | $28.2M | -33% |
| Q1 2025 | $26.2M | -35% |
| Q3 2024 | $38.8M | -6.5% |
| Q2 2024 | $41.9M | -5.4% |
ANIK's revenue is recovering but still below its 2023 peak: $31M last quarter, up 10% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -2.3% | -35 points |
| Q2 2026 | 9.1% | +24 points |
| Q1 2026 | -19% | -2.2 points |
| Q4 2025 | 2.1% | N/A |
| Q3 2025 | 32% | +105 points |
| Q2 2025 | -15% | -15 points |
| Q1 2025 | -16% | -3.9 points |
| Q3 2024 | -72% | -54 points |
ANIK's operating margin was −2.3% last quarter, down 35 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over ANIK on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over ANIK on profitability, with a higher operating margin.
ANIK Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $6.7M | +35% |
| Q2 2026 | -$2.1M | -$477K |
| Q1 2026 | -$6.3M | -$3.3M |
| Q4 2025 | $4M | +1351% |
| Q3 2025 | $5M | +31% |
| Q2 2025 | -$1.7M | +$2.8M |
| Q1 2025 | -$3M | -$1M |
| Q4 2024 | $275K | -85% |
ANIK still generates free cash flow, though less than at its 2019 peak: $2M over the past year.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over ANIK on cash flow, with more consistent year-over-year improvement.
ANIK Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -2.4% | -329K shares |
| 1 year | -7.2% | -1M shares |
| 3 years | -8.5% | -1.2M shares |
| 5 years | -8.6% | -1.3M shares |
| Available history | -8.4% | -1.2M shares |
ANIK has the edge over LLY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $853,000 |
| Q1 2026 | $8.7M |
| Q4 2025 | $5.5M |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $4M |
| Q4 2024 | $5.6M |
ANIK spent $15M buying back its own shares over the past year, up 58% from the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
ANIK Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -14.7x | Net Cash |
| Q2 2026 | -3.0x | Net Cash |
| Q1 2026 | -7.6x | Net Cash |
| Q4 2025 | -8.8x | Net Cash |
| Q3 2025 | -1.9x | Net Cash |
| Q1 2022 | -36.9x | Net Cash |
| Q4 2021 | -10.4x | Net Cash |
| Q3 2021 | -45.8x | Net Cash |
ANIK has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
ANIK Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 35.5 | Neutral |
| Stochastic | 29.4 | Neutral |
ANIK's weekly RSI is 36 (neutral) and its Stochastic is 29 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
ANIK PE vs Healthcare Sector
| Metric | ANIK | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ANIK has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
ANIK Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $18.7 | 26% below |
| 20 week MA | $18.9 | 27% below |
| 50 week MA | $15.2 | 9% below |
| 100 week MA | $13.8 | 0.1% above |
| 200 week MA | $19.0 | 27% below |
ANIK's trend is mixed: it's above one of its five weekly moving averages, and 27% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over ANIK on trend strength, trading above more of its moving averages.
ANIK Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $52.8 | $43.2 | -18% |
| 2021 | $43.2 | $38.0 | -12% |
| 2022 | $38.0 | $27.9 | -27% |
| 2023 | $27.9 | $22.7 | -19% |
| 2024 | $22.7 | $16.2 | -28% |
| 2025 | $16.2 | $9.55 | -41% |
| 2026 YTD | $9.55 | $13.8 | +45% |
ANIK has the edge over LLY on returns for 2026, with the stronger performance.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.